相关实验视频

Updated: Jul 10, 2025

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

用生物药物治疗的炎症性肠病患者的药物清除

Tina Deyhim¹, Adam S Cheifetz¹, Konstantinos Papamichael¹

¹Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.

Journal of clinical medicine

|November 25, 2023

概括

生物疗法对炎症性肠病 (IBD) 有效,但反应各不相同. 药物清除显著影响IBD患者的治疗结果和个性化剂量策略.

科学领域:

胃肠病学胃肠病学
药理动力学药理动力学
免疫学免疫学免疫学

背景情况:

生物疗法对于中度至严重的炎症性肠病 (IBD) 是至关重要的.
显著比例的患者经历了对抗瘤坏死因子 (TNF) 治疗的初级不响应或响应丧失.
不良结果与机械失败或药理动力学 (PK) 问题有关,特别是由于药物清除率高而导致药物暴露不足.

研究的目的:

审查影响IBD生物药物清除的变量.
检查药物清除与治疗结果之间的关联.
评估清除监测和基于模型的精确剂量 (MIPD) 在IBD管理中的作用.

主要方法:

综合文献综述. 这是一个全面的文献综述.
分析影响生物药物清除的因素 (例如体重,白蛋白,免疫性).
探索药物清除,药物度和临床反应之间的关系.

主要成果:

生物药物的加速清除与体重增加,血清白蛋白低,免疫性等因素有关.
新出现的数据表明,在IBD中药物清除和治疗结果之间存在强烈的联系.
基于模型的精确剂量 (MIPD) 工具利用清除来优化针对目标药物度的剂量.

结论:

药物清除是影响IBD生物疗法的疗效的关键因素.
了解和监测药物清除可以指导个性化剂量策略 (治疗药物监测).
需要进一步的研究来确定清除监测和MIPD在IBD常规临床实践中的确切作用.

关键词:

对抗TNF的治疗方法.获得许可证的时间.炎症性肠病是一种炎症性肠病.在这里,我们看到了Mirikizumab.基于模型的准确剂量准确剂量.药物动力学仪表板上的药物动力学仪表板他们的风险是kizumabb.治疗药物监测治疗药物监测乌斯蒂基诺姆巴布 (乌斯蒂基诺姆巴布) 是我已经看到了Vedolizumab.

更多相关视频

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...